Qiagen NV (QIA)

46.170
+0.550(+1.21%)
  • Volume:
    455,198
  • Bid/Ask:
    46.005/46.175
  • Day's Range:
    45.260 - 46.170

QIA Overview

Prev. Close
46.17
Day's Range
45.26-46.17
Revenue
1.07B
Open
45.72
52 wk Range
37.95-49.37
EPS
2.15
Volume
455,198
Market Cap
10.57B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
412,288
P/E Ratio
23.13
Beta
0.416
1-Year Change
5.1%
Shares Outstanding
227,700,000
Next Earnings Date
May 02, 2023
What is your sentiment on Qiagen?
or
Market is currently closed. Voting is open during market hours.

Qiagen NV News

Qiagen NV Analysis

Qiagen NV Company Profile

Qiagen NV Company Profile

Employees
6100
Market
Germany
  • Type:Equity
  • Market:Germany
  • ISIN:NL0012169213
  • WKN:A2DKCH

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Read More

Analyst Price Target

Average52.773 (+14.301% Upside)
High61.224
Low43.362
Price46.170
No. of Analysts8
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuySellBuy
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Buy
  • this one will keep riding as long as there is covid19
    2